12 completed, 8 terminated, 3 not yet recruiting, 3 unknown. 11 Phase 3, 8 Phase 2, 5 Not applicable, 1 Phase 1, 1 Phase 4.
Follow Vaso-occlusive Crisis: new trials by email Literature Review of Vaso-occlusive Crisis trials Research Report on Vaso-occlusive Crisis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adaptive Platform Trial for Pain Management in Sickle Cell Vaso-Occlusive Crisis Group 02 Paracetamol + Morphine + Ketamine, Group 01 Control: Paracetamol + Morphine, Group 03 : Paracetamol + Morphine + Nefopam - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 4 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 400 | 2026-10-01 | 2026-09-18 |
| Outcomes of Vaso-occlusive Crisis in Pediatric Sickle Cell Disease No intervention - Sickle Cell Disease, Vaso-occlusive Crisis | Not yet recruiting | Assiut University | 25 | 2025-10-01 | 2025-10-01 | |
| Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric Sufentanil - Vaso-occlusive Crisis | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 182 | 2024-05-02 | 2023-12-26 |
| Sex Hormones and Inflammatory Biomarkers in Patients With Sickle Cell Disease Sickle Cell Disease, Vaso-occlusive Crisis | Completed | University of Pennsylvania | 52 | 2024-03-01 | 2025-08-05 | |
| Oral Ketamine for Treatment of Vaso-Occlusive Pain Ketamine Hydrochloride - Vaso-occlusive Crisis | Phase 1 | Completed | Boston Children's Hospital | 10 | 2023-05-26 | 2026-09-28 |
| Hyperbaric-oxygen Therapy (HBOT) Versus Placebo for Treating Vaso-Occlusive Crisis (VOC) in Sickle Cell Disease (SCD) HBOT in Hyperbaric chamber, Hyperbaric chamber for placebo - Sickle Cell Disease, Hyperbaric Oxygen Therapy | Phase 3 | Unknown | University Hospital, Geneva | 100 | 2022-09-15 | 2022-11-02 |
| Hyperbaric Oxygen Therapy in Sickle Cell Pain hyperbaric oxygen therapy - Vaso-occlusive Crisis, Sickle Cell Anemia Crisis | Not applicable | Completed | University of Nebraska | 8 | 2022-09-01 | 2026-07-28 |
| A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease Inclacumab - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 3 | Terminated | Pfizer | 242 | 2022-03-29 | 2025-12-17 |
| A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises Inclacumab, Placebo - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 3 | Terminated | Pfizer | 72 | 2021-12-09 | 2024-12-11 |
| A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises Inclacumab, Placebo - Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease | Phase 3 | Completed | Pfizer | 241 | 2021-10-04 | 2025-12-02 |
| Evaluation of Virtual Reality to Save Morphinic in the Treatment of Vaso-occlusive Seizures of Sickle Cell Patients Consulting in the Emergency Room Virtual Reality, Usual Care - Vaso-occlusive Crisis, Sickle Cell Disease | Not applicable | Completed | Assistance Publique - Hôpitaux de Paris | 97 | 2021-03-04 | 2021-10-18 |
| Intranasal Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in the PED Intranasal ketamine - Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease | Phase 3 | Terminated | Abigail Nixon | 5 | 2019-12-19 | 2024-11-18 |
| Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia Omega 3, Vit D, Zinc sulfate - Vaso-occlusive Crisis, Sickle Cell Disease | Phase 2 / Phase 3 | Completed | Beni-Suef University | 350 | 2019-11-01 | 2021-01-27 |
| Music Therapy in Sickle Cell Disease Vaso-occlusive Crisis Music therapy program MUSIC CARE® + standard care, standard care of vaso-occlusive crises - Vaso-occlusive Crisis | Not applicable | Unknown | Assistance Publique - Hôpitaux de Paris | 40 | 2018-09-28 | 2019-10-21 |
| Study of Erythrocyte Parameters and Hypercoagulability in Sickle Cell Disease (SCD-TGA) Erythrocytic parameters and thrombin generation assay measurement - Sickle Cell Disease, Vaso-occlusive Crisis | Unknown | BILLOIR | 200 | 2018-09-01 | 2022-05-24 | |
| Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease Virtual Reality Therapy - Sickle Cell Disease, Vaso-occlusive Crisis | Not applicable | Recruiting | St. Jude Children's Research Hospital | 76 | 2018-02-05 | 2026-05-18 |
| Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis Ketamine - Sickle Cell Disease, Vaso-Occlusive Crisis | Phase 2 | Completed | UCSF Benioff Children's Hospital Oakland | 62 | 2016-06-01 | 2021-04-20 |
| Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease Rivipansel - Sickle Cell Anemia, Sickle Cell Disease | Phase 3 | Terminated | GlycoMimetics Incorporated | 154 | 2015-12-16 | 2021-02-10 |
| Apixaban in Patients With Sickle Cell Disease Apixaban, Placebo - Vaso-occlusive Crisis, Reduction in Hospitalizations | Phase 3 | Terminated | Nirmish Shah | 16 | 2015-01-01 | 2020-03-11 |
| Nitrous Oxide Analgesia Vaso-occlusive Crisis Nitrous oxide 50% - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 2 | Completed | Columbia University | 5 | 2013-11-12 | 2026-01-28 |
Showing 20 of 28. Sign in to see all of them.
Vaso-Occlusive Crises (28) · Anemia, Sickle Cell (25) · Agnosia (3) · Hematologic Diseases (3) · Acute Chest Syndrome (2) · Emergencies (2) · Pain (2) · Sickle Cell Trait (2) · Thrombophilia (1)
Anemia (28) · Anemia, Hemolytic (28) · Anemia, Hemolytic, Congenital (28) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (28) · Genetic Diseases, Inborn (28) · Hemic and Lymphatic Diseases (28) · Hemoglobinopathies (28) · Hematologic Diseases (25) · Pathological Conditions, Signs and Symptoms (6) · Neurologic Manifestations (5) · Signs and Symptoms (5) · Anemia, Sickle Cell (3) · Nervous System Diseases (3) · Neurobehavioral Manifestations (3) · Perceptual Disorders (3)
Ketamine (3) · inclacumab (3) · Hyperbaric Oxygenation (2) · Morphine (2) · rivipansel (2) · Analgesia, Patient-Controlled (1) · Cardiovascular Agents (1) · Dalteparin (1) · Docosahexaenoic Acids (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Hydroxyurea (1) · Ketoprofen (1) · Nefopam (1) · Saline Solution (1) · Simvastatin (1)
Assistance Publique - Hôpitaux de Paris (5) · Pfizer (3) · Anthera Pharmaceuticals (2) · GlycoMimetics Incorporated (2) · Abigail Nixon (1) · Assiut University (1) · BILLOIR (1) · Baylor College of Medicine (1) · Beni-Suef University (1) · Boston Children's Hospital (1) · Columbia University (1) · Duke University (1) · Johns Hopkins University (1) · Mast Therapeutics, Inc. (1) · Nirmish Shah (1)
United States (19) · France (7) · Brazil (4) · Lebanon (4) · Oman (4) · Saudi Arabia (4) · Turkey (Türkiye) (4) · Colombia (3) · Egypt (3) · Kenya (3) · Nigeria (3) · Canada (2) · Tanzania (2) · Belgium (1) · Dominican Republic (1)
Nirmish Shah, MD (2) · Ahmed F Mahmoud Hussein, MS.c (1) · Claire Heilbronner, MD, PhD (1) · Daniel S Tsze, MD, MPH (1) · Edwin L. Parsley, D.O. (1) · Helen Thackray, MD (1) · Jeff S Cooper, MD (1) · Jonathan B Cooper-Sood, MD (1) · Marilyn J Telen, MD (1) · Michael Frett, MD (1)
PMID 10861320, PMID 16267411, PMID 1710777, PMID 20001619, PMID 21131035, PMID 22129980, PMID 23813607, PMID 23874164, PMID 25733584, PMID 33877274, PMID 35120836, PMID 35981565, PMID 40862241, PMID 41315052
2019 (2)